These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37071946)

  • 21. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19.
    Harrington C; Bailey A; Delorme E; Hano S; Evans EA
    Subst Use Misuse; 2023; 58(2):266-274. PubMed ID: 36510800
    [No Abstract]   [Full Text] [Related]  

  • 22. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 24. Get It in Writing: How to Make Medications for Opioid Use Disorder Available During Incarceration.
    McGladrey M; Kelsch J; Lofwall MR; Fanucchi LC; Walsh SL; Oser CB
    J Correct Health Care; 2024 Feb; 30(1):3-6. PubMed ID: 38150232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts.
    Evans EA; Pivovarova E; Senthilkumar R; Rottapel RE; Stopka TJ; Santelices C; Ferguson WJ; Friedmann PD
    Int J Drug Policy; 2023 Dec; 122():104252. PubMed ID: 37980776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
    Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
    Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative.
    Krawczyk N; Bandara S; Merritt S; Shah H; Duncan A; McEntee B; Schiff M; Ahmad NJ; Whaley S; Latimore A; Saloner B
    Addict Sci Clin Pract; 2022 Jun; 17(1):30. PubMed ID: 35655293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts.
    Matsumoto A; Santelices C; Evans EA; Pivovarova E; Stopka TJ; Ferguson WJ; Friedmann PD
    Int J Drug Policy; 2022 Nov; 109():103823. PubMed ID: 35994938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
    Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
    Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of a large jail-based methadone maintenance treatment continuation program in New Mexico.
    Horn BP; Li X; McCrady B; Guerin P; French MT
    J Subst Abuse Treat; 2020 Aug; 115():108042. PubMed ID: 32600623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial Management of Incarcerated Pregnant Women With Opioid Use Disorder.
    O'Connor A; Bowling N
    J Correct Health Care; 2020 Jan; 26(1):17-26. PubMed ID: 31960750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment access for opioid use disorder among women with medicaid in Florida.
    Elmore AL; Patrick SW; McNeer E; Fryer K; Reid CN; Sappenfield WM; Mehra S; Salemi JL; Marshall J
    Drug Alcohol Depend; 2023 May; 246():109854. PubMed ID: 37001322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.
    Corry B; Underwood N; Cremer LJ; Rooks-Peck CR; Jones C
    Drug Alcohol Depend; 2022 Jul; 236():109495. PubMed ID: 35605533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facilitators and barriers to adopting or expanding medications for opioid use disorder provision in rural Colorado jails: a qualitative analysis.
    McNeely HL; Schreiber TL; Swann WL; Amura CR
    Health Justice; 2024 Jun; 12(1):26. PubMed ID: 38842589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
    Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
    Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medications for opioid use disorder during pregnancy: Access and continuity in a state women's prison facility, 2016-2019.
    Knittel AK; Swartzwelder RA; Zarnick S; Tsujimoto THM; Horne T; Lin FC; Edwards J; Amos E; Alexander J; Thorp J; Jones HE
    Drug Alcohol Depend; 2022 Mar; 232():109308. PubMed ID: 35074696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives.
    Pivovarova E; Evans EA; Stopka TJ; Santelices C; Ferguson WJ; Friedmann PD
    Drug Alcohol Depend; 2022 May; 234():109394. PubMed ID: 35349918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
    Dadiomov D; Trotzky-Sirr R; Shooshtari A; Qato DM
    Drug Alcohol Depend; 2022 Mar; 232():109291. PubMed ID: 35033953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.